Hemorrhoids Treatment Market Driven by Aging Population and Rising Pregnancy Cases

Hemorrhoids Treatment Market Size, Treatments and Top Players with Regional Analysis

The global hemorrhoids treatment market size is calculated at USD 1.21 billion in 2025, grew to USD 1.28 billion in 2026, and is projected to reach around USD 2.18 billion by 2035. The market is expanding at a CAGR of 6.05% between 2026 and 2035.

The hemorrhoids treatment market is primarily driven by the growing geriatric population and pregnancy among women. Hemorrhoids are commonly caused by straining during bowel movements, chronic constipation or diarrhea, and weakening of the supporting tissues in the anus or rectum. The growing research and development activities and the increasing investments by government and private organizations foster the market. Artificial intelligence (AI) revolutionizes the effective treatment of hemorrhoids.

Key Takeaways

• Hemorrhoids treatment market to crossed USD 1.21 billion by 2025.
• Market projected at USD 2.18 billion by 2035.
• CAGR of 6.05% expected in between 2026 to 2035.
• North America held a major revenue share of approximately 35% in the market in 2024.
• Asia-Pacific is expected to witness the fastest growth with a CAGR of 10% during the predicted timeframe.
• By treatment type, the pharmacological treatments segment dominated the hemorrhoids treatment market with a share of approximately 45% in 2024.
• By treatment type, the minimally invasive procedures segment is expected to witness the fastest growth with a CAGR of approximately 8% in the market over the forecast period.
• By hemorrhoid type, the internal hemorrhoids segment accounted for the highest revenue share of approximately 55% in the market in 2024.
• By hemorrhoid type, the mixed hemorrhoids segment is expected to expand rapidly in the market with a CAGR of approximately 7% in the coming years.
• By route of administration, the topical segment held the largest revenue share of approximately 50% in the market in 2024.
• By route of administration, the device-assisted treatment segment is expected to grow at the fastest CAGR of approximately 10% in the hemorrhoids treatment market during the forecast period.
• By end-user, the retail pharmacies & drug stores segment contributed the biggest revenue share of approximately 40% in the market in 2024.
• By end-user, the ambulatory surgical centers segment is expected to show the fastest growth with a CAGR of approximately 10% over the forecast period.
• By distribution channel, the over-the-counter (OTC) segment held a dominant revenue share of approximately 55% in the market in 2024.
• By distribution channel, the direct-to-consumer (D2C)/online segment is expected to grow with the highest CAGR of approximately 12% in the market during the studied years.

Quick Facts Table

Hemorrhoids Treatment: Pain-Free Pathways

The hemorrhoids treatment market is experiencing robust growth, driven by rising prevalence due to sedentary lifestyles, aging populations, chronic constipation, pregnancy-related cases, and increasing availability of minimally invasive outpatient procedures with shorter recovery times. It includes pharmaceuticals, minimally invasive procedures, surgical interventions, medical devices, and supportive care products used to treat internal and external hemorrhoids. Therapies include OTC and prescription medications, non-surgical office-based procedures, surgical hemorrhoidectomy, stapled hemorrhoidopexy, lifestyle and dietary interventions, and supportive care products.

Hemorrhoids Treatment Market Outlook

• Industry Growth Overview: The market is expected to accelerate due to the increasing development of regenerative medicines and the availability of robotic-assisted surgeries. AI-based diagnostic tools also enable patients to diagnose hemorrhoids at an early stage.
• Major Investors: Private equity firms and venture capital investors provide funding to pharmaceutical and biopharmaceutical companies to conduct research and clinical trials related to hemorrhoid therapeutics. They also fund healthcare organizations to adopt advanced surgical tools.
• Global Expansion: Key players collaborate to expand their geographical presence and deliver their proprietary products to a wider consumer base across diverse locations. This strengthens a company’s position in the market.

Automation Revolutionizes the Hemorrhoids Treatment Market

AI and machine learning (ML) algorithms transform the diagnosis and treatment of hemorrhoids. They enhance the accuracy, precision, and high speed of hemorrhoid treatment. They analyze large datasets of patient outcomes and recommend personalized treatment plans. They assist researchers in developing customized treatment plans for long-term relief. AI-enabled robots improve precision in hemorrhoid surgery, reducing blood loss, complications, and recovery time. AI can analyze patient anatomy and severity to assist surgeons in planning minimally invasive laser surgeries.

Segmental Insights

Treatment Type Insights

Which Treatment Type Segment Dominated the Hemorrhoids Treatment Market?

Pharmacological Treatments

The pharmacological treatments segment held a dominant presence in the market with a share of approximately 45% in 2024, due to high affordability and the need for non-invasive treatment. Pharmacological treatments include medications that treat a disease effectively. The availability of over-the-counter (OTC) medicines for hemorrhoid treatment also boosts the segment’s growth. OTC medicines enhance affordability, accessibility, and patient convenience, making them a suitable treatment option.

Minimally Invasive Procedures

The minimally invasive procedures segment is expected to grow at the fastest CAGR of approximately 8% in the market during the forecast period. The demand for minimally invasive procedures is increasing as they provide superior symptomatic relief, leading to faster recovery and lower recurrence. Surgeries offer targeted treatment to patients and completely remove the risk of disease recurrence.

Supportive Care Products

The supportive care products segment is expected to grow significantly, due to the growing demand for non-pharmacological treatment. Supportive treatments, such as sitz baths, wipes & pads, and dietary fiber supplements, provide supplementary care to patients with hemorrhoids. They provide synergistic therapeutic effects to patients, enabling them to relieve symptoms faster.

Hemorrhoid Type Insights

Why Did the Internal Hemorrhoids Segment Dominate the Hemorrhoids Treatment Market?

Internal Hemorrhoids

The internal hemorrhoids segment held the largest revenue share of approximately 55% in the market in 2024, due to the growing geriatric population and the rising prevalence of internal hemorrhoids. Internal hemorrhoids affect over half of the population by the age of 50. It leads to swollen veins inside the rectum that are usually not painful but can bring discomfort and bleeding. It can be treated with self-care methods and lifestyle adjustments.

Mixed Hemorrhoids

The mixed hemorrhoids segment is expected to grow with the highest CAGR of approximately 7% in the market during the studied years. Mixed hemorrhoids occur when both internal and external hemorrhoids exist at the same time. They are comparatively more severe than internal or external hemorrhoids. Surgery is the most effective and strongly recommended treatment for patients with mixed hemorrhoids.

External Hemorrhoids

The external hemorrhoids segment is expected to grow at a notable CAGR. External hemorrhoids are swollen veins under the skin around the anus. Common treatment regimens for external hemorrhoids include topical products and a cold compress. External hemorrhoids account for approximately 20% of all hemorrhoid cases in the world.

Route of Administration Insights

How the Topical Segment Dominated the Hemorrhoids Treatment Market?

Topical

The topical segment contributed the biggest revenue share of approximately 50% in the market in 2024, due to the need for targeted therapeutic effects and high patient convenience. Creams, ointments, and pads with hydrocortisone and lidocaine are applied to the affected part. They provide topical relief of the symptoms associated with hemorrhoids, such as swelling, itching, and pain. The topical route is preferred by patients of all age groups.

Device-assisted Treatment

The device-assisted treatment segment is expected to expand rapidly in the market with a CAGR of approximately 10% in the coming years. Advancements in medical technologies and the growing demand for minimally invasive surgeries contribute to the segment’s growth. Medical devices assist surgeons in endoscopy, laser-assisted hemorrhoidoplasty, and physical therapy. The integration of AI/ML in medical devices enhances their functionality and improves accuracy.

Injectable

The injectable segment is expected to grow in the coming years. Injections are given to patients undergoing sclerotherapy. A special chemical solution, sclerosant, is injected into the area around the hemorrhoid, triggering a scarring reaction. This makes the hemorrhoid gradually shrink or shrivel up over time. Injections offer high bioavailability and a faster onset of action.

End-User Insights

Which End-User Segment Led the Hemorrhoids Treatment Market?

Retail Pharmacies & Drug Stores

The retail pharmacies & drug stores segment led the market with a share of approximately 40% in 2024, due to the availability of a favorable infrastructure and the presence of skilled professionals. Skilled professionals provide tailored guidance to patients about hemorrhoid treatment. Retail pharmacies store a variety of products, including OTC and generic alternatives. They offer numerous benefits, such as specialized discounts and 24/7 facilities.

Ambulatory Surgical Centers

The ambulatory surgical centers segment is expected to witness the fastest growth with a CAGR of approximately 10% in the market over the forecast period. Ambulatory surgical centers (ASCs) are emerging as effective sites for minimally invasive surgeries. Patients prefer visiting ASCs as they provide personalized outpatient services. This eliminates the need for patients to stay overnight, saving exorbitant costs.

Online Pharmacies

The online pharmacies segment is expected to show a lucrative growth, driven by the burgeoning e-commerce sector and the growing geriatric population. Online pharmacies enable patients to order the desired medications from the comfort of their homes. Patients can compare prices of different products, allowing them to purchase high-quality products at affordable rates. Online pharmacies offer numerous benefits, such as free home delivery and virtual consultations.

Distribution Channel Insights

What Made Over-the-Counter (OTC) the Dominant Segment in the Hemorrhoids Treatment Market?

Over-the-Counter (OTC)

The over-the-counter (OTC) segment accounted for the highest revenue share of approximately 55% in the market in 2024, due to its high affordability and increasing awareness of self-medication. Certain pain relievers do not need a doctor’s prescription. OTC drugs are usually preferred by patients during the early stages of hemorrhoids. According to a recent systematic review and meta-analysis, the prevalence rate of self-medication in India is 64.4%.

Direct-to-Consumer (D2C)/Online

The direct-to-consumer (D2C)/online segment is expected to show the fastest growth with a CAGR of approximately 12% over the forecast period. Manufacturers and developers have the right to sell their proprietary products to patients through online platforms directly. This eliminates the need for wholesalers and distributors, reducing extra costs. Online platforms enable manufacturers to reach a wider consumer base across different geographical locations.

Prescription-based

The prescription-based segment is expected to grow in the upcoming years. Corticosteroids, anesthetics, and astringents require prescriptions to administer to a patient. They are needed for surgeries or pre-surgical care. Anesthetics are used to make a patient unconscious either locally or generally, based on the type of surgery. Local anesthetics may also help alleviate pain and soreness.

Regional Analysis

Which Factors Contribute to the Hemorrhoids Treatment Market in North America?

North America dominated the global market with a share of approximately 35% in 2024. The availability of a robust healthcare infrastructure and state-of-the-art research and development facilities are the factors that contribute to market growth in North America. Favorable regulatory policies and a suitable clinical trial infrastructure lead to the development of novel, innovative medicines and medical devices. Increasing investments and collaborations among key players facilitate market growth.

Favorable Clinical Trial Infrastructure Dominated the U.S.

Healthcare organizations, such as Johns Hopkins Medicine, Hemorrhoid Centers of America, and Harvard Health, provide hemorrhoid treatment to Americans. As of November 18, 2025, a total of 218 clinical trials are registered on the clinicaltrials.gov website related to hemorrhoids, of which 29 are registered in the U.S.

How is Asia-Pacific Growing in the Hemorrhoids Treatment Market?

Asia-Pacific is expected to grow at the fastest CAGR of approximately 10% in the market during the forecast period. The rising prevalence of hemorrhoids and growing research and development activities boost the market. The burgeoning healthcare sector and the presence of healthcare organizations with advanced facilities augment market growth. Government bodies provide funding and launch initiatives to adopt advanced surgical tools and build appropriate facilities in hospitals and clinics.

Natural Remedies Fuel China’s Growth

China accounts for the highest number of hemorrhoid cases globally. It is estimated that the prevalence of hemorrhoidal disease in China is around 50.28%. People mostly prefer Traditional Chinese Medicine (TCM) for a variety of diseases, including hemorrhoids. In 2023, TCM healthcare institutions provided diagnoses and treatment to 1.28 billion people in China.

Will Europe Grow in the Hemorrhoids Treatment Market?

Europe is expected to grow at a considerable CAGR in the upcoming period. Favorable government support and the rising adoption of advanced technologies propel market growth. The presence of key players leads to the development of novel products and the offering of personalized treatment to patients. The Hemorrhoid Clinic London, AmberCell Solutions, and Hila are major players in the field of hemorrhoid treatment.

Burgeoning Healthcare Sector to Drive Germany

Germany’s advanced healthcare system ensures the wide availability of hemorrhoid treatment in state-of-the-art facilities nationwide. Approximately 50,000 hemorrhoid surgeries are performed annually in Germany. The availability of health insurance increases the affordability of hemorrhoid care. Statutory health insurance (SHI) or substitutive private health insurance (PHI) provides health insurance to Germans.

South America's Increasing Patient Load

South America’s hemorrhoids treatment market growth stems from a large, increasing patient population. Sedentary lifestyles are linked to a rise in symptomatic cases across the region. Latest professional reports show a strong patient preference for minimally invasive procedures, like rubber band ligation, due to their quicker recovery times.

Brazil's Minimally Invasive Procedure Growth

Brazil, a major country, sees a high patient volume driven by lifestyle factors like a poor diet. Brazilian specialists report diagnosing hemorrhoidal disease in approximately 35% of all treated patients. This patient surge is boosting the adoption of advanced techniques and new outpatient medical procedures for better outcomes.

MEA Region Patient Adoption Surges

The Middle East and Africa show a strong patient base, with up to one-quarter of the population over 50 experiencing symptoms. Improved healthcare access is encouraging more patients to seek care. This trend is accelerating the use of modern procedures, including infrared coagulation and other laser-based options in clinics.

GCC's Advanced Technology Patient Focus

The GCC hemorrhoids treatment market is characterized by patients seeking premium, advanced hemorrhoid treatment technologies. Increasing rates of obesity and low-fiber diets contribute to a growing patient count. The patient's focus is highly directed towards innovative procedures such as Doppler-guided artery ligation for minimal discomfort and quicker return to work.

Company Landscape

Company 1: Medtronic plc

Company Overview

• Company Overview: A global healthcare technology leader, providing a broad range of medical devices, therapies, and services. It is a major player in the Hemorrhoid Treatment Devices market, focusing on surgical and minimally invasive instruments.

Corporate Information (Headquarters, Year Founded, Ownership Type)

• Headquarters: Dublin, Ireland (Operational headquarters in Fridley, Minnesota, USA)
• Year Founded: 1949
• Ownership Type: Public (NYSE: MDT)

History and Background

• History and Background: Started in a garage in Minneapolis as a medical equipment repair shop. Grew to become a pioneer in implantable cardiac pacemakers and expanded into multiple therapeutic areas, becoming one of the largest medical technology companies globally.

Key Milestones/Timeline:

• Key Milestones/Timeline: 
  • 1949: Founded by Earl Bakken and Palmer Hermundslie.
  • 2015: Completed the acquisition of Covidien, significantly expanding its surgical and medical supplies portfolio.
  • 2024/2025: Continued focus on expanding its surgical innovations and minimally invasive therapy offerings within its portfolio.

Business Overview

• Business Overview: Provides technology and therapies to treat nearly 70 health conditions, including cardiac, surgical, neurological, and diabetes-related issues. The hemorrhoid treatment products fall under its Minimally Invasive Therapies Group.

Business Segments/Divisions:

• Cardiovascular Portfolio
• Neuroscience Portfolio
• Medical Surgical Portfolio (includes minimally invasive surgical products like staplers and energy devices relevant to advanced hemorrhoidectomy)
• Diabetes

Geographic Presence

• Geographic Presence: Operates in more than 150 countries, with a significant presence in North America, Europe, and the Asia Pacific.

Key Offerings:

• Surgical Stapling Systems: Used for procedures like Stapled Hemorrhoidopexy (PPH).
• Advanced Energy Devices (e.g., LigaSure): Used for vessel sealing and cutting in surgical hemorrhoidectomy, offering faster, less painful procedures.
• Minimally invasive tools for colorectal procedures.

End-Use Industries Served:

• Hospitals and Clinics
• Ambulatory Surgical Centers (ASCs)
• Physicians and Surgeons (Colorectal, General Surgery)

Key Developments and Strategic Initiatives

• Mergers & Acquisitions: Continual evaluation of tuck-in acquisitions to strengthen its Medical Surgical portfolio. 
• Partnerships & Collaborations: Engages in collaborations with healthcare providers and group purchasing organizations (GPOs) to streamline technology adoption.
• Product Launches/Innovations: Ongoing development and launch of enhanced surgical instruments and single-use devices, often focused on improving patient outcomes and OR efficiency.
• Capacity Expansions/Investments: Continuous investment in manufacturing and R&D facilities globally to support its broad product portfolio.
• Regulatory Approvals: Secures necessary clearances (e.g., FDA, CE Mark) for its surgical devices, including updated clearances for specific colorectal applications in 2024.
• Distribution channel strategy: A mix of direct sales channels, distributors, and e-commerce platforms, particularly focusing on ASCs and major hospital networks.

Technological Capabilities/R&D Focus

• Technological Capabilities/R&D Focus: Focus on surgical visualization, advanced energy delivery, and robotics to make surgical procedures less invasive and more precise.
• Core Technologies/Patents: Patents related to surgical stapling technology, vessel sealing (LigaSure), and minimally invasive surgical tools.
• Research & Development Infrastructure: Over $2.7 billion spent annually on R&D, with centers of excellence worldwide.
• Innovation Focus Areas: Smart surgery, robotics (e.g., Hugo system), and improved tissue management in abdominal and colorectal surgery.

Competitive Positioning

• Strengths & Differentiators: Global scale, strong brand reputation in medical devices, comprehensive portfolio of advanced surgical instruments, deep hospital relationships.
• Market presence & ecosystem role: A dominant force in the high-value surgical devices market, setting standards for stapled hemorrhoidopexy and energy-based excision.

SWOT Analysis:

• Strengths: Global market leadership, strong R&D pipeline, diversified product offerings.
• Weaknesses: High cost of advanced devices, exposure to currency fluctuations.
• Opportunities: Growth in minimally invasive procedures (MIS), expansion in emerging markets (MEA, APAC).
• Threats: Intense competition from Johnson & Johnson and Boston Scientific, increasing regulatory scrutiny.

Recent News and Updates

• Press Releases: Focused on clinical data supporting its surgical products and expansions in its robotics platform (2024/2025).
• Industry Recognitions/Awards: Frequently recognized for innovation in surgical technology and corporate governance.

Company 2: Johnson & Johnson (J&J)

Company Overview

• Company Overview: A multinational corporation that focuses on pharmaceutical, medical device, and consumer health products. J&J's presence in hemorrhoid treatment is primarily through its Ethicon surgical technology division and its Consumer Health segment (e.g., OTC topical products).

Corporate Information (Headquarters, Year Founded, Ownership Type)

• Headquarters: New Brunswick, New Jersey, USA
• Year Founded: 1886
• Ownership Type: Public (NYSE: JNJ)

History and Background

• History and Background: Founded by three brothers (Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson) as a surgical dressings company. Pioneered sterile surgical supplies and became a diversified healthcare leader over the next century.

Key Milestones/Timeline

• Key Milestones/Timeline: 
  • 1886: Founded.
  • 1999: Ethicon launched its PPH (Procedure for Prolapse and Hemorrhoids) stapler, a key product in the hemorrhoid surgical space.
  • 2023/2024: J&J completed the separation of its Consumer Health business into a new publicly traded company, Kenvue, but still retains a significant presence in the medical device sector through Ethicon.

Business Overview

• Business Overview: Post-split, J&J's primary focus is on Pharmaceuticals and MedTech (Medical Devices). The hemorrhoid device market is addressed by the MedTech segment, specifically under Ethicon.

Business Segments/Divisions

• Business Segments/Divisions: 
  • Pharmaceuticals (Janssen)
  • MedTech (Includes Ethicon, focusing on surgery)

Geographic Presence

• Geographic Presence: Operates and sells products in virtually every country globally, making it a truly multinational corporation.

Key Offerings

• Key Offerings: 
  • Ethicon Circular Staplers (e.g., PPH systems): Essential for Stapled Hemorrhoidopexy, a procedure for internal hemorrhoids.
  • Surgical instruments and wound closure products: Used in traditional and advanced hemorrhoidectomy. 
  • OTC products (Historically, some brands are now under Kenvue, but the core MedTech presence remains).

End-Use Industries Served

• End-Use Industries Served: 
  • Hospitals and Clinics (Primary focus for Ethicon)
  • Ambulatory Surgical Centers (ASCs)
  • General, Colorectal, and Bariatric Surgeons

Key Developments and Strategic Initiatives

• Mergers & Acquisitions: Continued focus on strategic acquisitions within MedTech to enhance surgical portfolio, such as the acquisition of Abiomed in late 2022 to boost its Cardiovascular segment.
• Partnerships & Collaborations: Works with major institutions for clinical studies and training, maintaining a large network of surgical product adoption.
• Product Launches/Innovations: Ongoing innovation in surgical stapling and energy devices to improve tissue handling and reduce complications in procedures like PPH.
• Capacity Expansions/Investments: Major investments in digital surgery and robotic platforms to maintain a competitive edge.
• Regulatory Approvals: Continuous efforts to secure new clearances for its advanced surgical tools globally in 2024.
• Distribution channel strategy: Leverages a vast, established global distribution network, predominantly direct sales to hospitals for high-value surgical devices.

Technological Capabilities/R&D Focus

• Technological Capabilities/R&D Focus: Focus on digital surgery, advanced visualization, robotics, and stapling technology to make surgical procedures more predictable and less invasive.
• Core Technologies/Patents: Extensive patent portfolio covering surgical staplers, wound closure devices, and energy-based surgical instruments.
• Research & Development Infrastructure: R&D spending was over $15 billion in 2023, showcasing a massive commitment to innovation across all healthcare sectors.
• Innovation Focus Areas: Robotics (VELYS, Monarch), digital surgery ecosystems, and next-generation electrosurgery.

Competitive Positioning

• Strengths & Differentiators: Global brand recognition, massive R&D budget, dominant position in surgical staples (Ethicon), separation of Consumer Health simplifies focus on MedTech.
• Market presence & ecosystem role: A fundamental part of the global surgical ecosystem, often being the benchmark for quality and safety in stapled and energy-based surgical procedures.

SWOT Analysis

• SWOT Analysis: 
  • Strengths: Unmatched brand equity, diversified business model, leadership in surgical technology (Ethicon).
  • Weaknesses: High operating scale complexity, potential litigation risk related to some legacy devices.
  • Opportunities: Rapid adoption of digital surgery and robotics, market entry in developing economies.
  • Threats: Aggressive competition from Medtronic and other surgical device makers, downward pressure on healthcare costs.

Recent News and Updates

• Press Releases: Announcements in 2024 focused on the performance of its MedTech segment and new regulatory approvals for its surgical platforms in the US and EU.
• Industry Recognitions/Awards: Regularly receives awards for innovation in medical technology and is highly rated for corporate responsibility.

Top Companies & Their Offerings in the Hemorrhoids Treatment Market

Other Companies

• RG Hospitals
• Abbott Laboratories
• AstraZeneca
• Boston Scientific
• Olympus Corporation
• Conmed
• PACE Hospitals
• Cook Medical

Recent Developments in the Hemorrhoids Treatment Market

• In June 2025, a general surgeon at the Osmania General Hospital (OGH) developed an innovative painless hybrid laser sandwich procedure for hemorrhoids. The treatment is devised for people suffering from grade-3 and grade-4 hemorrhoids. The procedure offers the benefits of both conventional and laser surgery, providing patients with faster relief.
• In January 2025, Lux Hospitals launched the ENDOANAL Real-time Ultrasound-Guided Laser Procedure for treating Fistula in Ano. The procedure leverages real-time ultrasound guidance with advanced laser technology to provide highly effective treatment.

Segments Covered in the Report

By Treatment Type

• Pharmacological Treatments 
  • Topical Creams & Ointments
  • Oral Medications (flavonoids, pain relievers)
• Minimally Invasive Procedures 
  • Rubber Band Ligation
  • Sclerotherapy
  • Infrared Coagulation (IRC)
  • Laser Therapy
• Surgical Interventions 
  • Hemorrhoidectomy
  • Stapled Hemorrhoidopexy
• Supportive Care Products 
  • Sitz Baths
  • Wipes & Pads
  • Dietary Fiber Supplements

By Hemorrhoid Type

• Internal Hemorrhoids
• External Hemorrhoids
• Mixed Hemorrhoids

By Route of Administration

• Topical
• Oral
• Injectable
• Device-assisted Treatment

By End-User

• Retail Pharmacies & Drug Stores
• Ambulatory Surgical Centers (ASCs)
• Hospitals
• Clinics/Proctology Centers
• Online Pharmacies

By Distribution Channel

• Over-the-Counter (OTC)
• Prescription-based
• Direct-to-Consumer (D2C)/Online

By Region

• North America 
  • US
  • Canada
  • Mexico
  • Rest of North America
• South America 
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus
    • Turkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific (APAC) 
  • China
  • Taiwan
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA) 
  • GCC Countries 
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA